Injection site reactions Injection site reactions with tirzepatide are common and usually mild, including redness, itching, and minor swelling
Great Product
Body weight, though not directly factored into dosing algorithms, influences pharmacokinetics
For a complete breakdown, see our detailed 2.5mg unit conversion guide
While this effect may help regulate appetite, blood sugar, and body weight, plaintiffs allege it can also lead to severe stomach issues in some patients
The Therapeutic Goods Administration's (TGA) warning covers the following glucagon-like peptide-1 (GLP-1) receptor agonists, which are used to treat type 2 diabetes and obesity: Semaglutide, sold as Ozempic, Wegovy Tirzepatide, sold as Mounjaro Dulaglutide, sold as Trulicity Liraglutide, sold as Saxenda The TGA said the products had the potential to cause an eye disorder called non-arteritic anterior ischaemic optic neuropathy (NAION)